Cellevate announces the appointment of renowned industrial biotechnology and bioprocessing expert Dr. Uwe Gottschalk as new Chairman of the Board of Directors
LUND, Sweden, March 14, 2024 – Cellevate AB, an innovative biotech company developing the next generation of cell culture systems designed to revolutionize biomanufacturing, announces that Dr. Uwe Gottschalk has been elected as Chairman to its Board of Directors. The appointment follows the resignation of Mats Leifland, who served as Chairman of the Board until March 12, 2024.Dr. Gottschalk brings a wealth of experience within the field of biotechnology, boasting a distinguished career highlighted by significant achievements. He currently serves as an Operating Partner at Keensight Capital.